Validating the Utility of the Milan System of Reporting Salivary Gland Cytopathology for the Diagnosis of Salivary Gland Fine-Needle Aspirates in a North Indian Tertiary Care Center and Comparing the Risk of Malignancy with its Two Editions

在印度北部一家三级医疗中心验证米兰唾液腺细胞病理学报告系统在唾液腺细针穿刺诊断中的实用性,并比较其两个版本恶性肿瘤风险

阅读:1

Abstract

BACKGROUND: Salivary gland (SG) fine-needle aspiration (FNA) is a well-accepted tool for preoperative management of salivary gland lesions (SGLs). First and second editions of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) were published in the years 2018 and 2023, respectively. The MSRSGC aims to improve patient care by providing better communication between clinicians and institutions. It has six ascending diagnostic categories having a definite risk of malignancy (ROM) and corresponding management schema. Our study assessed the incidence and corresponding ROM of each MSRSGC category within a tertiary care northern India referral center and compared each ROM with those laid down in the two editions of the MSRSGC. AIMS AND OBJECTIVES: The main aims and objectives are as follows:1. Validating the utility of the MSRSGC for the diagnosis of SG-FNAs in a North Indian Tertiary Care Center.2. Comparing the Risk of Malignancy with its Two Editions. MATERIALS AND METHODS: Data on SG-FNAs performed between 01.01.2010 and 31.03.2024 were searched from the hospital information system. The cytopathology and histopathological slides were retrieved, and each case was separately reviewed and retrospectively classified into the I) non-diagnostic (ND), II) non-neoplastic (NN), III) atypia of undetermined significance (AUS), IVA) benign neoplasms (NB), IVB) SG neoplasm of uncertain malignant potential (SUMP), V) suspicious for malignancy (SFM), or VI) malignant categories according to the MSRSGC. Cyto-histopathological correlation analysis was performed, and the ROM for each category was calculated. RESULTS: A total of 793 such cases were obtained. Histopathological follow-up was available in 267 cases, which included 2 (0.7%) ND, 29 (10.9%) NN, 5 (1.9%) AUS, 190 (71.2%) NB, 11 (4.1%) SUMP, 10 (3.7%) SFM, and 20 (7.5%) malignant cases. The calculated ROM for these ascending categories were 0%, 27.6%, 60%, 11.8%, 45.5%, 90%, and 100%, respectively. CONCLUSION: MSRSGC is a valuable means to standardize the reporting and preoperatively stratify SGLs as per the ROM for each ascending risk category. This study, to the best of our knowledge, is the largest Indian study to authenticate the utility and reproducibility of the MSRSGC in our tertiary care institute.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。